Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection

被引：90

作者：

Xie, Yong ^{[1
]}

Zhu, Yin ^{[1
]}

Zhou, Hong ^{[1
]}

Lu, Zhi-Fa ^{[1
]}

Yang, Zhen ^{[1
]}

Shu, Xu ^{[1
]}

Guo, Xiao-Bai ^{[2
]}

Fan, Hui-Zhen ^{[3
]}

Tang, Jian-Hua ^{[4
]}

Zeng, Xue-Ping ^{[5
]}

Wen, Jian-Bo ^{[6
]}

Li, Xiao-Qing ^{[7
]}

He, Xing-Xing ^{[1
]}

Ma, Jiu-Hong ^{[1
]}

Liu, Dong-Sheng ^{[1
]}

Huang, Cai-Bin ^{[8
]}

Xu, Ning-Jian ^{[9
]}

Wang, Nong-Rong ^{[10
]}

Lu, Nong-Hua ^{[1
]}

机构：

[1] Nanchang Univ, Affiliated Hosp 1, Dept Gastroenterol, Nanchang 330006, Jiangxi, Peoples R China

[2] Jiangxi Prov Peoples Hosp, Dept Gastroenterol, Nanchang 330006, Jiangxi, Peoples R China

[3] Peoples Hosp Yichun City, Dept Gastroenterol, Yichun 336000, Jiangxi, Peoples R China

[4] Ganzhou Peoples Hosp, Dept Gastroenterol, Ganzhou 341000, Jiangxi, Peoples R China

[5] Third Hosp Nanchang, Dept Gastroenterol, Nanchang 330009, Jiangxi, Peoples R China

[6] Pingxiang Peoples Hosp, Dept Gastroenterol, Pingxiang 337000, Jiangxi, Peoples R China

[7] Fengcheng Peoples Hosp, Dept Gastroenterol, Fengcheng 331100, Jiangxi, Peoples R China

[8] Gannan Med Coll, Affiliated Hosp 1, Dept Gastroenterol, Ganzhou 341000, Jiangxi, Peoples R China

[9] Yingtan City Peoples Hosp, Dept Gastroenterol, Yingtan 335000, Jiangxi, Peoples R China

[10] Nanchang Univ, Affiliated Hosp 4, Dept Gastroenterol, Nanchang 330003, Jiangxi, Peoples R China

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2014年 / 20卷 / 32期

关键词：

Helicobacter pylori infection; Furazolidone; Treatment; Eradication; ANTIBIOTIC-RESISTANCE; SEQUENTIAL THERAPY; CONSENSUS REPORT; CONTROLLED-TRIAL; METRONIDAZOLE; BISMUTH; CLARITHROMYCIN; LEVOFLOXACIN; RABEPRAZOLE; MANAGEMENT;

D O I：

10.3748/wjg.v20.i32.11415

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

AIM: To evaluate the efficacy of furazolidone-based triple and quadruple therapy in eradicating Helicobacter pylori (H. pylori) in a multi-center randomized controlled trial. METHODS: A total of 720 H. pylori positive patients with duodenal ulcer disease were enrolled at 10 different hospitals in Jiangxi province in China. The patients were randomly assigned to four treatment groups as follows: patients in Groups 1 and 3 received rabeprazole (10 mg), amoxicillin (1000 mg) and furazolidone (100 mg) twice daily for 7 and 10 d, respectively; patients in Groups 2 and 4 received rabeprazole (10 mg), bismuth (220 mg), amoxicillin (1000 mg) and furazolidone (100 mg) twice daily for 7 and 10 d, respectively. The primary outcome measure was H. pylori eradication rate 4 wk after treatment by intention-to-treat and per protocol analysis, while the secondary outcome measures were symptom and sign changes at the end of treatment and 4 wk after the end of treatment, as well as the proportion of patients who developed adverse events. RESULTS: The demographic data of the four groups were not significantly different. Overall, 666 patients completed the scheme and were re-assessed with the C-13-urea breath test. The intention-to-treat analysis of the H. pylori eradication rates in Groups 1, 2, 3 and 4 were 74.44%, 82.78%, 78.89% and 86.11%, respectively. The H. pylori eradication rate in Group 4 was significantly higher than that in Group 1. According to the per protocol analysis, the H. pylori eradication rates in Groups 1, 2, 3 and 4 were 81.21%, 89.22%, 85.54% and 92.26%, respectively. The H. pylori eradication rate in Group 4 was significantly higher than that in Group 1. The number of adverse events was 15 (8.3%), 16 (8.9%), 15 (8.3%) and 17 (9.4%) in Groups 1, 2, 3 and 4, respectively, including dizziness, vomiting, diarrhea, nausea, skin rash, itchy skin, and malaise. The symptoms were relieved without special treatment in all of the patients. CONCLUSION: Both 7- and 10-d quadruple furazolidone-based therapies achieve satisfactory H. pylori eradication rates. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.

引用

页码：11415 / 11421

页数：7

共 24 条

[1]

Furazolidone, Co-amoxiclav, Colloidal Bismuth Subcitrate, and Esomeprazole for Patients Who Failed to Eradicate Helicobacter pylori with Triple Therapy [J].